Richard A. ZAGER,Donald Jeffrey KEYSER,Alvaro F. GUILLEM
申请号：
US16422156
公开号：
US20200057076A1
申请日:
2019.05.24
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
